The LUCINAE Registry is an international, multicenter observational study collecting data on patients with thoracic cancers (including lung cancer) who are expecting a child. This includes women diagnosed during pregnancy, women who become pregnant during or after cancer, and men receiving cancer treatment at the time their partner conceives.
Because thoracic cancers during pregnancy are rare, there is limited information to guide clinical decisions. This registry aims to describe patient characteristics, diagnostic approaches, treatments, and maternal and fetal outcomes. Data are collected retrospectively and prospectively from participating centers.
The results of this registry are expected to improve understanding of thoracic cancers in this setting and support the development of future clinical recommendations.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* 1\. All patients with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities) and pregnancy (positive pregnancy test) including:
1. Patients receiving a diagnosis of thoracic cancer during pregnancy
2. Patients who became pregnant while having active thoracic cancer
3. Patients previously treated for a thoracic cancer and becoming pregnant in the 5 years following end of treatment OR Men with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities), who were undergoing active oncological treatment at the time their partner conceived their child.
* 2\. Available information about pregnancy outcomes
* 3\. Age ≥ 18 years
Exclusion Criteria:
* 1\. Patient missing data about thoracic cancer stage and diagnosis
* 2\. For retrospective patients, documented refusal to the use of clinical data for research purposes
Primary outcome measure(s)
Timing of diagnosis — At the moment of patient enrolment Timing of cancer diagnosis with respect to the onset of pregnancy.
Modality of diagnosis — At the moment of patient enrolment Method used for cancer diagnosis.
Duration of treatment — Throughout study participation, up to 5 years after delivery. Duration of the treatment received during the pregnancy
Maternal outcome — At the conclusion of pregnancy. Survival of the mother at the end of gestation.
Fetal outcome — At the conclusion of pregnancy. Survival of the fetus at the end of gestation.
Trial sites (4)
Facility
City
Region
Status
Kantonsspital Baden
Baden
Switzerland
Recruiting
Istituto Oncologico della Svizzera Italiana (IOSI)
Bellinzona
Switzerland
Recruiting
Geneva University Hospital (HUG)
Geneva
Switzerland
Recruiting
Kantonsspital Winterthur
Winterthur
Switzerland
Recruiting
More Oncology Institute of Southern Switzerland trials in Switzerland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
